cvot trials in diabetes ppt - Adapted from WittbrodtET et al Generalizability normal diabetes berapa of GLP1 RA Cardiovascular Outcomes Trials Enrollment Criteria to the US Type 2 Diabetes Population Poster presented at the America Diabetes Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes MD Chairin Diabetes Research Director Florida Hospital Diabetes Institute Senior Scientist Translational Research Institute for Metabolism and Diabetes Stephen Gough MD FRCP UK Type 2 Diabetes N3297 6 CVOT Trial Design Randomized Dose Escalation 48 weeks co33 Followup 5 weeks Semaglutide 1 mg Placebo 1 mg Placebo 05 mg Key CVOTs with Semaglutide SUSTAIN 6 and PIONEER 6 Cardiovascular disease CVD is the leading cause of death and morbidity in people with diabetes In 2017 the total cost of diagnosed diabetes in the United States was 327 billion and CVD is the largest contributor to the direct and indirect costs of diabetes 23Diabetes is a wellestablished risk factor for CVD in a retrospective study of nearly 14 million individuals with type 2 trials 12 weeks duration 19 trials 9459 subjects Linagliptin versus placeboactive treatment 122 MACE events MACE HR 078 055 111 CARMELINA Dedicated CV Cardiovascular disease is the leading cause of death and complications in patients with type 2 diabetes 1 Recently trials evaluating a sodiumglucose cotransporter 2 inhibitor empagliflozin Cardiovascular outcomes trials a paradigm shift in the current Cardiovascular Outcomes Trials in Patients with Diabetes Issues Type 2 diabetes is a major risk factor for cardiovascular disease 12 and the presence of both type 2 diabetes and cardiovascular what causes pre diabetes disease increases the risk of death 3 Evidence that glucose After 10 Years and 26 CVOTs Where do We Stand on CV Safety in Diabetes These trials were designed and conducted in accordance with the 2008 US Food and Drug Administration FDA guidance for evaluating CV safety in new glucoselowering therapies 5 In both trials at least 122 first MACE were required to rule out a hazard ratio of 18 preapproval boundary for noninferiority assessment The SUSTAIN 6 CVOT was Type 2 Diabetes DPP4i dipep7dyl pep7dase 4 inhibitor CANVAS Canagliflozin Cardiovascular Assessment Study CAROLINA Cardiovascular Outcom es Study of Linaglip7n Versus Glimepiride in Pa7ents with Type 2 Diabetes C SCADE 8 trial of empagliflozin CVOT cardiovascular outcomes trials DECLARE Dapagliflozin Effect on Cardiovascular Cardiovascular Outcome Trials in Type 2 Diabetes What Do They Mean for The DECLARETIMI 58 trial was a randomized doubleblind multinational placebocontrolled phase 3 trial of dapagliflozin in patients with type 2 diabetes and established atherosclerotic Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes PDF PowerPoint Presentation Cardiovascular disease CVD is the leading cause of mortality and morbidity in patients with type 2 diabetes T2D Historical concerns about cardiovascular CV risks associated with certain glucoselowering medications gave rise to the introduction of cardiovascular outcomes trials CVOTs Initially implemented to help monitor the CV safety of glucoselowering drugs in patients with T2D PDF Cardiovascular Outcomes Trials in Type 2 Diabetes Semaglutide and Cardiovascular Outcomes in Patients diabetes boleh makan pisang with Type 2 Diabetes
diagnosa keperawatan keluarga dengan diabetes melitus
cek diabetes dimana
